The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.

CAR-T pipeline advances, with blood cancers at the forefront of development, driving new treatment innovations.

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...

While the allogeneic vs autologous debate continues in the cell therapy field, research on in vivo therapies is drawing ...

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

Poor physical function correlated with outcomes among patients with non-Hodgkin lymphoma who underwent chimeric antigen ...

Legend Biotech), tisagenlecleucel (Kymriah, Novartis), brexucabtagene autoleucel (Tecartus, Kite Pharma/Gilead Sciences) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead Sciences).

Who Are the Key Players in the Kymriah Market? The Kymriah market is dominated by Novartis AG, a key player in CAR-T cell therapy innovation. Advancements in Kymriah and other CAR-T therapies have ...

Novartis is paying Kyorin $55 million upfront for exclusive global rights to develop, manufacture and commercialize KRP-M223, a preclinical mast-cell-targeting candidate for chronic spontaneous ...

No­var­tis is spend­ing $55 mil­lion on glob­al rights to Ky­orin Phar­ma­ceu­ti­cal’s pre­clin­i­cal drug for in­flam­ma­to­ry dis­eases in a deal that comes al­most two ...